secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lineage Cell Therapeutics, Inc. (LCTX)
CIK:        0000876343
Form:       8-K
Filed at:   2026-03-05T23:59:59+00:00
Accession:  0001193125-26-093948
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lineage Q4 net income $0.9M, full-year loss $63.5M; cash runway into Q2 2028
----------------------------------------------------------------------------

- Q4 2025 revenue $6.6M (up from $2.9M YoY); net income $0.9M ($0.004 EPS) vs net loss $3.3M ($0.02 loss) in Q4 2024.
- Full-year 2025 net loss $63.5M ($0.28/share) vs $18.6M ($0.09/share) in 2024; driven by non-cash warrant remeasurement ($37.9M) and VAC impairment ($14.8M).
- Cash $55.8M at Dec 31, 2025; plus $5.4M from warrant exercises in March 2026; expected to support operations into Q2 2028.
- Achieved first milestone under Roche/Genentech collaboration for OpRegen; 36-month Phase 1/2a data shows sustained visual acuity gains.
- Launched Type 1 diabetes research initiative; treated first chronic SCI patient in OPC1 DOSED study with no safety events at 180 days.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/876343/000119312526093948/0001193125-26-093948-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/876343/000119312526093948/lctx-20260305.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-093948

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer